Changchun High-Tech: Leuprolide Acetate Injection Granted Drug Registration Certificate

36Kr reports that Changchun High-Tech announced its subsidiary, Jinsai Pharmaceutical, received the 'Drug Registration Certificate' approved and issued by the National Medical Products Administration. The application for overseas production drug registration and market launch of Leuprolide Acetate Injection (6M) has been approved, with indications for prostate cancer requiring androgen deprivation therapy. As a long-acting subcutaneous injection formulation administered every six months, the product can improve patient compliance. This approval is expected to enrich the company's product portfolio in the oncology field and enhance its market competitiveness.